US · BBNX
Beta Bionics, Inc.
- Sector
- Healthcare · Medical - Equipment & Services
- Headquarters
- Irvine, CA 92618
- Website
- betabionics.com
Price · as of 2025-12-31
$10.29
Market cap 560.55M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $44.01 | +327.7% |
| Intrinsic Value(DCF) | $981.63 | +9,439.65% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $16.14 | $47.82 | $10,612,233.25 | $0.00 | $0.00 |
| 2025 | $12.52 | $44.01 | $5,534.87 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Beta Bionics, Inc.'s (BBNX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $44.01
- Current price
- $10.29
- AI upside
- +327.7%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$981.63
+9,439.65% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BBNX | Beta Bionics, Inc. | $10.29 | 560.55M | +328% | +9,440% | — | — | -6.93 | 1.76 | 5.06 | -4.11 | — | 1.76 | 55.40% | -71.50% | -73.02% | -40.26% | -236.00% | -30.60% | 0.04 | — | 8.66 | 7.64 | 0.26 | -7895.00% | 5394.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -4.20 | — | 3.00 | 6.28 |
| AHCO | AdaptHealth Corp. | $9.15 | 1.24B | +239% | -53% | — | — | -19.73 | 0.86 | 0.40 | 2.75 | — | -1.18 | 17.52% | 5.74% | -2.18% | -4.27% | 7.18% | -1.50% | 0.12 | 1.76 | 1.02 | 0.67 | 0.16 | -18525.00% | -49.00% | -696.00% | 16.84% | 0.84 | 8.45% | 0.00% | 0.00% | 148.90% | 7.43 | 6.31 | 0.43 | 0.97 |
| DVAX | Dynavax Technologies Corp… | $15.50 | 1.82B | +159% | -40% | -64% | -64% | 68.57 | 3.14 | 6.75 | 30.92 | — | 3.15 | 82.17% | -1.49% | 9.85% | 4.48% | -2.66% | 2.75% | 0.43 | -0.61 | 10.80 | 9.67 | 3.47 | -50323.00% | 1936.00% | -3763.00% | 3.21% | 0.85 | 43.90% | 0.00% | 0.00% | 5.34% | -342.86 | 23.49 | 5.10 | 2.81 |
| IMTX | Immatics N.V. | $10.34 | 1.39B | +1,496% | -51% | -32% | +199% | 28.44 | 0.75 | 2.78 | -4.51 | — | 0.76 | 100.00% | -24.78% | 9.77% | 3.80% | 27.69% | 2.52% | 0.03 | -43.58 | 9.26 | 8.99 | -6.40 | -11167.00% | 18860.00% | 127096.00% | -40.32% | -2.32 | 175.55% | 0.00% | 0.00% | 4.04% | 4.03 | 0.89 | -1.00 | 1.96 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $23.28 | 1.36B | +67% | +283% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| ORIC | ORIC Pharmaceuticals, Inc… | $13.45 | 1.31B | — | — | — | — | -9.41 | 3.17 | — | -7.40 | — | 3.17 | 0.00% | — | — | -41.27% | -272.98% | -37.79% | 0.03 | — | 14.13 | 13.79 | 0.27 | -1967.00% | — | 20.00% | -9.36% | -5.55 | -217.77% | 0.00% | 0.00% | 0.00% | -6.63 | -8.32 | — | 24.72 |
| PGEN | Precigen, Inc. | $3.79 | 1.14B | +633% | -73% | — | +239% | -3.94 | 12.93 | 126.87 | -3.28 | -19.23 | 33.38 | -8.71% | -3440.23% | -3216.18% | -160.80% | -3010.47% | -85.20% | 0.14 | -22504.83 | 4.76 | 4.60 | 0.19 | 2051.00% | -3695.00% | 1211.00% | -15.41% | -3.17 | -1735.60% | 0.00% | 0.00% | 4.73% | -3.00 | -5.28 | 103.33 | -19.72 |
| PLSE | Pulse Biosciences, Inc. | $18.73 | 1.27B | — | — | — | — | -17.46 | 15.75 | 3629.72 | -16.69 | -100.37 | 16.44 | -360.00% | -21982.57% | -20794.57% | -74.45% | -1168.13% | -63.68% | 0.09 | — | 10.53 | 10.22 | 1.02 | 1739.00% | — | 4927.00% | -4.29% | -6.83 | -826.49% | 0.00% | 0.00% | 0.00% | -15.56 | -21.99 | 3420.56 | 40.87 |
| STAA | STAAR Surgical Company | $19.90 | 982.38M | +92% | -59% | -70% | — | -44.58 | 2.27 | 2.87 | -123.99 | — | 2.28 | 76.32% | -4.02% | -6.44% | -5.16% | -6.20% | -4.05% | 0.10 | — | 5.23 | 4.41 | 18.43 | -19535.00% | -264.00% | 11338.00% | -0.85% | 0.22 | -3.77% | 0.00% | 0.00% | 0.17% | -56.24 | -92.48 | 2.26 | 5.87 |
| TERN | Terns Pharmaceuticals, In… | $42.12 | 3.79B | — | — | — | — | -3.12 | 0.80 | — | 0.79 | — | 0.80 | 0.00% | — | — | -29.56% | 1106.27% | -28.10% | 0.00 | — | 23.14 | 22.89 | 1.59 | -1181.00% | — | 388.00% | -25.25% | -4.47 | 760.80% | 0.00% | 0.00% | 29.11% | 0.78 | 1.13 | — | 7.82 |
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
- CEO
- Sean T. Saint
- Employees
- 352
- Beta
- 5.65
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($981.63 ÷ $10.29) − 1 = +9,439.65% (DCF, example).